Advertisement

Editor Profile

JoAnne M. Foody, MD

Associate Editor

About the NEJM Journal Watch Cardiology Board

JoAnne M. Foody, MD, is Director of the Cardiovascular Wellness Center at Brigham and Women’s Hospital in Boston. Dr. Foody has an active role in inpatient care and mentors residents and fellows, with emphasis on strengthening cardiac disease prevention and rehabilitation. Her research has focused on identifying and fostering greater use of clinical strategies that prevent adverse cardiovascular events in people with and without coronary artery disease. Dr. Foody also has had leadership roles on the National AMI and National Heart Failure projects of the Centers for Medicare & Medicaid Services. She has been writing for NEJM Journal Watch Cardiology since 2000.

Disclosures

Consultant / Advisory board

Aegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societies

American College of Cardiology, Cardiosmart (Co-chair)

Summaries by Joanne Foody

  • June 4, 2014

    Pour It On: Extra-Virgin Olive Oil Could Reduce AF Risk

    1. JoAnne M. Foody, MD

    Post-hoc PREDIMED study findings suggest antiarrhythmic as well as anti-ischemic benefits of a Mediterranean diet with an extra helping of EVOO.

  • June 4, 2014

    Sex Differences in Coronary Microvascular Dysfunction?

    1. JoAnne M. Foody, MD

    The prevalence and implications of CMD are similar in both men and women and could serve as a useful marker of risk.

  • May 9, 2014

    Never Too Late to Adopt Healthy Habits

    1. JoAnne M. Foody

    In the CARDIA cohort, young adults who acquired or dropped healthy lifestyle factors had concordant increases or decreases in markers of atherosclerosis.

  • April 28, 2014

    Update on the Evidence for PCSK9 Inhibition to Lower LDL Cholesterol

    1. JoAnne M. Foody, MD

    Findings from three 12-week trials and a 1-year trial show promise for evolocumab, but we don't yet have outcomes data.

  • March 30, 2014

    Darapladib Fails to Reduce Cardiovascular Events

    1. JoAnne M. Foody, MD

    In the prospective, randomized STABILITY trial, lipoprotein-associated phospholipase A2 inhibition did not improve the primary clinical outcomes.

  • February 18, 2014

    Sodium Intake: The Less, the Better

    1. JoAnne M. Foody, MD

    A retrospective analysis of urinary sodium excretion in a prehypertensive cohort shows a linear association with cardiovascular events.

Pages